Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides. 1995

A Malmberg, and N Mohell
Department of Molecular Pharmacology, Preclinical R & D, Astra Arcus AB, Södertälje, Sweden.

The in vitro receptor binding characteristics of [3H]quinpirole to cloned human dopamine D2A (long isoform) and D3 receptors were investigated and compared with those of rat striatal dopamine receptors. [3H]Quinpirole selectively labeled the high-affinity state of cloned dopamine D2A and striatal D2 receptors with an affinity of about 4 nM. In the striatum, [3H]quinpirole bound to 70% of the receptors labeled by the antagonist [3H]raclopride, whereas the corresponding value for cloned dopamine D2A receptors was 26%. [3H]Quinpirole labeled both the high- and "low-"affinity states of the dopamine D3 receptor with the affinities of 0.6 nM (36% of the receptors) and 7.3 nM, respectively. At all three receptors, sodium decreased the proportion of receptors labeled by [3H]quinpirole, whereas its affinity for the remaining high-affinity sites was not changed. Further addition of guanine nucleotides completely converted the high-affinity binding into low. Thus, even the dopamine D3 receptor was regulated by sodium and guanine nucleotides. Competition studies for [3H]quinpirole and [3H]raclopride binding revealed that the agonists (+)-(R)-7-hydroxy-2-dipropylaminotetralin and quinpirole, previously claimed to be highly dopamine D3-selective (approximately 100-fold), displayed high affinity for the high-affinity agonist states of both dopamine D2 and D3 receptors. When these values were compared, instead of the apparent affinities from the one-site analysis, the dopamine D3-selectivities were 20-fold for (+)-(R)-7-hydroxy-2-dipropylaminotetralin and 8-fold for quinpirole. Thus, it is of importance to consider both high- and low-affinity agonist states when receptor selectivities are evaluated.

UI MeSH Term Description Entries
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008297 Male Males
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D006165 Guanylyl Imidodiphosphate A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+. The nucleotide is a potent stimulator of ADENYLYL CYCLASES. GMP-PNP,GMP-P(NH)P,Gpp(NH)p,Guanosine 5'-(Beta,Gamma-Imido)Triphosphate,Guanyl-5'-Imidodiphosphate,P(NH)PPG,Guanyl 5' Imidodiphosphate,Imidodiphosphate, Guanylyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012457 Salicylamides Amides of salicylic acid.
D012964 Sodium A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23. Sodium Ion Level,Sodium-23,Ion Level, Sodium,Level, Sodium Ion,Sodium 23

Related Publications

A Malmberg, and N Mohell
February 1992, European journal of pharmacology,
A Malmberg, and N Mohell
September 1992, The Journal of pharmacology and experimental therapeutics,
A Malmberg, and N Mohell
October 1991, European journal of pharmacology,
A Malmberg, and N Mohell
February 1993, The Journal of pharmacology and experimental therapeutics,
A Malmberg, and N Mohell
August 1985, The Journal of pharmacology and experimental therapeutics,
A Malmberg, and N Mohell
November 1981, Biochemical pharmacology,
A Malmberg, and N Mohell
April 1979, Nature,
A Malmberg, and N Mohell
May 1979, European journal of pharmacology,
A Malmberg, and N Mohell
December 1997, Neuroscience letters,
Copied contents to your clipboard!